A West Virginia physician is reporting encouraging early results in treating a rare and aggressive form of leukemia — an outcome that could dramatically reduce treatment costs while improving the quality of life for patients.
WVU Medicine medical oncologist Ashkan Emadi is heading up a Morgantown-based clinical trial in the use of an anti-cancer drug that is injected just beneath the skin. The medicine, called blinatumomab, is already used in treating more common forms of leukemia, and it’s often infused over 28 days, which requires patients to be hospitalized, at least for the first treatment cycle.
What’s different about Dr. Emadi’s trial is that it doesn’t require hospitalization for the treatment of mixed phenotype acute leukemia, which dramatically improves the patient’s quality of life and could ultimately cut the cost of care.
Treatment costs for a similar type of leukemia for people ages 50 to 64 ranged between $200,000 and $550,000, according to a 2017 study that appeared in the journal “Biology of Blood and Marrow Transplant”.
But many adult cases of MPAL are diagnosed in people over age 65, which limits treatment options, said Dr. Emadi, who is the study’s principal investigator.
“The only cure for this disease is bone marrow transplant, but patients over age 75 or who have comorbidities are not eligible for transplants,” he said. “These people are not being treated. There’s no standard of care.”
Read More
There are dozens of types of leukemia, a disease that kills around 23,540 people a year. MPAL is quite rare, only affecting 1% to 3% of leukemia cases.
There are only an estimated 500 cases of MPAL in the U.S., Dr. Emadi said, 10,000 worldwide.
Survival rates vary dramatically, depending on the diagnostic criteria used, patient age and other factors, but the median survival rate for adults with MPAL was less than 11 months, according to a 2010 study in “Blood”, a publication of the American Society of Hematology.
“Patients with MPAL have faced an extraordinary therapeutic void,” Dr. Emadi said in a prepared statement. “This first in the world treatment offers real hope that can improve both outcomes and quality of life for a patient population that has been historically overlooked.”
In addition to the WVU Cancer Institute in Morgantown, the study will enroll patients at 15 other sites over four years. Early results have been encouraging: A 77-year-old woman experienced complete remission after the first cycle of treatment, which Dr. Emadi said was both “unprecedented and highly encouraging.”
“It’s very well tolerated so far,” he said about the injected medicine. “That’s a very good drug.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.